• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Jazz Pharmaceuticals Public Limited Company (JAZZ)

    150.45 Up 3.43(2.33%) Nov 25, 4:00PM EST
    ProfileGet Profile for:
    Jazz Pharmaceuticals Public Limited Company
    Connaught House
    Fourth Floor
    Dublin, 4
    Ireland - Map
    Phone: 353 1 634 7800
    Fax: 353 1 634 7850
    Website: http://www.jazzpharma.com

    Index Membership:N/A
    Full Time Employees:885

    Business Summary 

    Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Jazz Pharmaceuticals Public Limited Company

    Corporate Governance 
    Jazz Pharmaceuticals Public Limited Company’s ISS Governance QuickScore as of Nov 1, 2015 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Bruce C. Cozadd , 51
    Co-Founder, Exec. Chairman and Chief Exec. Officer
    Mr. Matthew P. Young , 46
    Chief Financial Officer and Exec. VP
    Mr. Russell J. Cox , 52
    Chief Operating Officer and Exec. VP
    Ms. Suzanne Sawochka Hooper , 49
    Exec. VP and Gen. Counsel
    Mr. Michael P. Miller , 58
    Sr. VP of U.S. Commercial
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders